Stock Track | TransMedics Group Plunges 21.52% in Pre-Market After Q1 Earnings Severely Miss Estimates

Stock Track05-06

TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which revealed a significant earnings miss and deteriorating profitability.

The medical technology company reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of approximately $0.61 by about 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and operating income fell 52% to $13.3 million. The company's gross margin also narrowed to 58% from 61% a year ago.

The earnings shortfall was primarily driven by higher operating expenses, including increased investments in research and development and organizational spending to support growth initiatives. Following the results, several analysts cut their price targets on the stock, reflecting heightened concerns over the company's profit margins and earnings trajectory despite reiterated full-year revenue guidance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119484864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119484864","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Group Plunges 21.52% in Pre-Market After Q1 Earnings Severely Miss Estimates","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which revealed a significant earnings miss and deteriorating profitability.</p><p>The medical technology company reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of approximately $0.61 by about 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and operating income fell 52% to $13.3 million. The company's gross margin also narrowed to 58% from 61% a year ago.</p><p>The earnings shortfall was primarily driven by higher operating expenses, including increased investments in research and development and organizational spending to support growth initiatives. Following the results, several analysts cut their price targets on the stock, reflecting heightened concerns over the company's profit margins and earnings trajectory despite reiterated full-year revenue guidance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Plunges 21.52% in Pre-Market After Q1 Earnings Severely Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Plunges 21.52% in Pre-Market After Q1 Earnings Severely Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which revealed a significant earnings miss and deteriorating profitability.</p><p>The medical technology company reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of approximately $0.61 by about 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and operating income fell 52% to $13.3 million. The company's gross margin also narrowed to 58% from 61% a year ago.</p><p>The earnings shortfall was primarily driven by higher operating expenses, including increased investments in research and development and organizational spending to support growth initiatives. Following the results, several analysts cut their price targets on the stock, reflecting heightened concerns over the company's profit margins and earnings trajectory despite reiterated full-year revenue guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1119484864","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119484864","pubTimestamp":1778056478,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|Q1盈利严重不及预期TransMedics Group盘前暴跌21.52%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) experienced a pre-market plunge of 21.52% on Wednesday. The sharp decline followed the release of the company's first-quarter fiscal year 2026 financial results, which revealed a significant earnings miss and deteriorating profitability.The medical technology company reported adjusted earnings per share of $0.30, missing the analyst consensus estimate of approximately $0.61 by about 50% and representing a 59% decline from the $0.74 reported in the same quarter last year. While revenue of $173.9 million slightly exceeded expectations, net income plummeted 72% year-over-year to $7.3 million, and operating income fell 52% to $13.3 million. The company's gross margin also narrowed to 58% from 61% a year ago.The earnings shortfall was primarily driven by higher operating expenses, including increased investments in research and development and organizational spending to support growth initiatives. Following the results, several analysts cut their price targets on the stock, reflecting heightened concerns over the company's profit margins and earnings trajectory despite reiterated full-year revenue guidance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119484864","isCrawlerRequest":true}